Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs AMG-596 (Primary)
- Indications Glioblastoma
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 15 Feb 2018 Planned initiation date changed from 9 Oct 2017 to 20 Mar 2018.
- 19 Oct 2017 Status changed from not yet recruiting to recruiting.
- 05 Oct 2017 New trial record